Outlook Therapeutics posts NORSE THREE results for ONS-5010 in retinal disorders
Results for the completed Phase 3 NORSE THREE trial of ONS-5010 (bevacizumab) were posted on ClinicalTrials.gov, showing adverse event data from 197 participants.
Outlook Therapeutics had one update this week: results posted for its completed Phase 3 safety trial of ONS-5010.
- NORSE THREE (NCT04516278) is a completed Phase 3 study that enrolled 197 participants in a single-group design testing ONS-5010, a 1.25 mg intravitreal injection of bevacizumab.1 The trial tested the drug in patients with an active clinical diagnosis and OCT confirmation of exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion who, in the investigator's opinion, needed anti-VEGF therapy.1 Results posted on 2026-07-17 showed 62 participants with adverse events and 11 out of 197 participants with serious adverse events.1 The study had an actual primary completion and study completion date of 2021-02-10.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.